Contexto sectorial
GeneDx Holdings Corp [WGS]
Última actualización 24 Jun 2026 @ 16:00 (Exchange is closed)
Último: $63.54
9.40%
1.02 (↑)
GaG Algo Score™
v1.0
Corto
1.02 (↑)
Medio
-0.29 (↑)
Largo
-0.56 (↑)
COMPRAR
68.00%
rentabilidad 26.74%
VENDER
59.18%
rentabilidad 15.88%
Línea
Datos pivot
Estadísticas pivot
| Métrica | Promedio | Mediana | Desv. est. |
|---|---|---|---|
| Ganancia % | 17.13% | 17.13% | 0.00% |
| Pérdida % | -50.58% | -50.58% | 0.00% |
| Duración | 12.5d | 13d | 0.7d |
| Pivots encontrados | 3 |
| Tramos ganancia/pérdida | 2 (1 Ganancia / 1 Pérdida) |
| Último pivot | Bottom @ $34.51 el 2026-05-05 |
| Cambio desde el último pivot | $23.57 (68.30%) |
Predicción del próximo pivot Último: $63.54
| Próximo tipo previsto | Top |
| Precio previsto (prom.) | $40.42 |
| Precio previsto (mediana) | $40.42 |
| Rango de precio previsto (~68%) | $40.42 - $40.42 |
| Cambio al objetivo promedio | $-23.12 (-36.39%) |
| Fecha prevista (prom.) | 2026-05-17 |
| Rango de fechas previsto (~68%) | 2026-05-16 - 2026-05-18 |
| Base | Based on 1 historical gains (Avg: 17.13%, Median: 17.13%, StdDev: 0.00%) and duration (Avg: 12.5 days, StdDev: 0.7 days) |
| Nota | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
Significant gain for GeneDx Holdings Corp, up 4.80%.
GeneDx Holdings Corp (WGS) stock price demonstrated dramatic improvement on Tuesday after the stock rose $2.66 (4.80%) from the previous session on normal volume. Showing significant relative strength, the stock rose today while the NASDAQ fell -0.43%. With 1.01M shares traded, volume yesterday reached $58.70M. This was 5 321 shares more than the prior day. Compared to the 10-day average of 1.12M shares, volume was the same as the average.
GeneDx Holdings Corp signals
There is no conclusive signals given from RSI. The price is above the short-term average yet below the long-term average, with the short-term average still below the long-term average; signals are mixed. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (3.3%), medium- (3.3%), and long-term (3.3%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
GeneDx Holdings Corp Support & Resistance Levels
The stock is approaching the closest resistance level at $62.30. approximately $4.22 (7.27%) away. Approaching it. Breaking above this level could signal further upside where next resistance level will be found at $66.9. On a fall back there will be support at $40.5 The dis das resistance s140.5 -
GeneDx Holdings Corp Evaluation
- Corto puntuación: 1.02
- Medio puntuación: -0.29
- Largo puntuación: -0.56
Flujo de propiedad
GetAGraph InsiderPower
Transacciones
584
Fuerza compradora
399.80M
Fuerza vendedora
326.18M
Fiabilidad
100/100
Compra / venta
1.23
Corr. hist.
-0.73
Última señal
Buy 2026-05-27
Officer 381
Director 177
Major holder 21
Other 5
2026-06-18
Ryan Jason Director
Buy 3 576
2026-06-18
Ruch Joshua Director
Buy 3 576
2026-06-18
Ruch Joshua Director
Buy 4 248
2026-06-18
Pfenniger Richard C Jr Director
Buy 3 576
2026-06-18
Pfenniger Richard C Jr Director
Buy 4 248
2026-06-18
Meister Keith A. Director
Buy 3 576
Mapa de relación
Resumen de correlación
<span style="background-color: lightcoral">Overvalued: <i class="arrow arrow-down"></i>0.63% <strong>$63.98</strong> paired level.</span>
Positioning pressure
Short interest pressure
Short interest
15.82%
Of outstanding shares
Short float
18.03%
Of tradable float
Days to cover
3.44
Short interest divided by average volume
Squeeze probability
84.30%
-7.31% change
Short positioning is elevated and could amplify sharp price moves.
Updated 2026-05-29Earnings quality
Earnings history
Reported quarters
10
EPS beats
7
EPS misses
3
Avg. surprise
192.75%
| Period | Date | Actual EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| Q3/2025 | 2025-10-27 | - | - | - | - |
| Q2/2025 | 2025-07-29 | - | $0.0900 | - | - |
| Q1/2025 | 2025-04-30 | $0.280 | $0.110 | 154.55% | 87.12M |
| Q4/2024 | 2025-02-18 | $0.700 | $0.0400 | 1 650.00% | 95.64M |
| Q3/2024 | 2024-10-29 | $0.0400 | $-0.190 | 121.05% | 76.87M |
| Q2/2024 | 2024-07-30 | $-0.110 | $-0.260 | 57.69% | 70.51M |
| ~2024 Q1? | 2024-04-29 | $-0.330 | $-0.680 | 51.47% | 62.42M |
| ~2023 Q4? | 2024-02-20 | $-0.590 | $-0.600 | 1.67% | 57.42M |
Analyst view
Analyst targets
Consensus
$86.86
Median
$75.00
Low
$63.00
High
$150.00
News flow
Latest company news
Market coverage
globenewswire.com GeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics Acquisition – Hagens Berman Jun 24, 2026 prnewswire.com Robbins LLP Urges WGS Stockholders Who Lost Money Investing in GeneDx Holdings Corp. to Contact the Firm for Information About Leading the Class Action Jun 24, 2026 newsfilecorp.com GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC Jun 24, 2026 feeds.newsfilecorp.com WGS CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026 Jun 24, 2026Company releases
Company context
Company profile
Bolsa:
NASDAQ
Sector:
Healthcare
Industria:
Medical Healthcare Information Services
Currency
USD
GeneDx Holdings Corp functions as a health intelligence firm singularly focused on the individual patient It aims to revolutionize healthcare delivery by deploying advanced artificial intelligence and machine learning capabilities These sophisticated algorithms are applied to vast longitudinal clinical and genomic datasets to construct comprehensive dynamic models of human health ultimately defining personalized optimal pathways for each persons wellbeing Through its exclusive Centrellis health intelligence platform the company gains profound insights into both disease states and overall wellness enabling it to furnish evidencebased solutions for the most critical medical challenges Eric Schadt established the corporation in October 2015 and its principal offices are located in Stamford Connecticut
Navigation